Penn Medicine Initiates Clinical Trial for Advanced FLASH Proton Therapy

The Abramson Cancer Center at the University of Pennsylvania has embarked on a pioneering Phase I clinical trial to explore a novel version of proton therapy for cancer treatment. Known as FLASH proton therapy, this innovative approach delivers high-dose radiation in under a second, potentially reducing the number of required sessions while minimizing adverse side effects. This marks the inaugural human trial of conformal FLASH proton therapy in the United States, targeting recurrent head and neck cancer.

The study will include 10 patients whose head and neck cancer has recurred following prior radiation treatments. These individuals are not candidates for surgical intervention, making them viable subjects for the trial. The goal is to assess whether this accelerated form of radiation therapy can enhance the quality of life by minimizing both treatment time and radiation-induced side effects, such as difficulties with eating, drinking, and swallowing.

As detailed by principal investigator Dr Alexander Lin, "Patients with recurrent, unresectable head and neck cancer face limited treatment options. Existing methods like repeat radiation are not only grueling because of significant side effects but also require a considerable time commitment. We aim to offer a therapy with reduced toxicity that is both convenient and effective, allowing patients more time for personal pursuits."

FLASH proton therapy departs from conventional radiation protocols, which typically involve daily treatments over several weeks. This new method delivers treatment in just five sessions over approximately 10 days, dramatically shortening the overall treatment timeline. The Roberts Proton Therapy Center in Philadelphia serves as the venue for the trial, casting the University of Pennsylvania as a leader in advancing proton therapy research.

Proton therapy itself is a specialized form of radiation therapy utilizing high-energy protons to damage and destroy cancer cell DNA. Penn Medicine's ComformalFLASH® proton therapy technique, backed by an Investigational Device Exemption from the FDA, leverages precise 3D targeting to maximize tumor impact while sparing healthy tissues.

James Metz, MD, chair of Radiation Oncology, commented on the significance of this trial, highlighting the integration of proton therapy's precision with conformal techniques. This trial represents a critical milestone in evaluating both the advantages and constraints of this investigational technology.

Should the trial prove successful, further studies will aim to expand its applications to a broader array of cancer types and later-phase trials focused on outcomes. Penn Medicine's collective research efforts signal a promising new direction in radiation therapy, elevating patient care and therapeutic efficiency.